India has announced plans to reduce the prices of 137 cancer medicines by up to 70 per cent, expanding government efforts to make cancer treatment more affordable and ease the financial burden on patients.

The Ministry of Chemicals and Fertilizers announced the decision on Saturday, stating that trade margins on the affected medicines would be capped at 30 per cent of their maximum retail prices.

The new measures, which take effect on November 9, cover a range of cancer treatments, including immunotherapy drugs used in treating more than 20 types of cancer. The affected medicines also include treatments for breast, prostate, colon, ovarian and cervical cancers.

The policy is expected to strengthen India's existing system of pharmaceutical price controls by limiting the margins that traders can charge on essential cancer medicines.

The latest intervention builds on measures introduced in 2019, when the Indian government imposed price controls on 42 anti-cancer drugs, resulting in price reductions of up to 90 per cent.

By extending the controls to an additional 137 medicines, the government is widening its efforts to improve access to cancer treatment in a country where the cost of long-term medical care can place considerable pressure on patients and their families.

The inclusion of immunotherapy medicines is particularly notable, given their use in treating various cancers and their growing role in modern cancer care.

The revised pricing arrangements are designed to limit trade margins and reduce the prices patients pay for the affected medicines. However, the actual savings will vary depending on the individual drug and its existing retail price.

The decision marks another step in India's efforts to regulate medicine prices and improve the affordability of essential treatments, with the new controls scheduled to come into force on November 9.